Data from Two Phase III Studies of Merck’s Investigational Asthma Drug Presented at American Academy of Allergy …
NEW ORLEANS—-Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology annual meeting.
Emergency Response Incident Case Study 1967 US Navy

Comments are closed